In order to enhance the efficacy of the KRAS vaccine and anti-PD-1 treatment, an anti-CD38 antibody (daratumumab) is being administered with the objective of facilitating the killing of cancer cells by the immune system [137]. This evidence concerns the gene KRAS and cancer.